Mirum Pharmaceuticals grants Myers 40K stock options

The options and restricted stock units follow separate vesting schedules, with the full RSU award vesting on the third anniversary of September 21, 2026.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Mirum Pharmaceuticals, Inc. (MIRM) Chief Medical Officer Robert Paul Myers received a grant on October 9, 2026, of employee stock options covering 40,000 common shares with an $86.01 exercise price and 25,000 restricted stock units. The options vest in installments beginning one year after September 21, 2026; the RSUs vest over three years.

Insider Trade Summary

Grant/Award: 65,000 shares

Grant/Award 2 txns

Insider Myers Robert Paul

Role Chief Medical Officer

Type	Security	Shares	Price	Value
Grant/Award	Employee Stock Option (right to buy) ^F1	40,000	$0.00	$0.00
Grant/Award	Restricted Stock Units ^{F2, F3}	25,000	$0.00	$0.00

Holdings After Transaction: Employee Stock Option (right to buy) — 40,000 contracts (Direct); Restricted Stock Units — 25,000 contracts (Direct)

Footnotes (3)

F1. 1/4th of the shares vest one year after September 21, 2026 (the "Vesting Commencement Date") and the balance of the shares vest in a series of 36 successive equal monthly installments measured from the first anniversary of the Vesting Commencement Date.
F2. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
F3. 1/3rd of the shares subject to the restricted stock units shall vest on each anniversary of September 21, 2026 (the "Vesting Commencement Date"), such that the entire award will be vested on the three-year anniversary of the Vesting Commencement Date.

Key Figures

Employee stock options: 40,000 options covering 40,000 common shares Option exercise price: $86.01 per share Restricted stock units: 25,000 units +2 more

5 metrics

Employee stock options 40,000 options covering 40,000 common shares Granted October 9, 2026

Option exercise price $86.01 per share Employee stock options granted October 9, 2026

Restricted stock units 25,000 units Granted October 9, 2026

Shares per restricted stock unit 1 share Each unit represents a contingent right to receive one share of common stock

Option vesting installments 36 successive equal monthly installments Balance of the option shares, measured from the first anniversary of September 21, 2026

Key Terms

Employee Stock Option (right to buy), Restricted Stock Units, Vesting Commencement Date

3 terms

Employee Stock Option (right to buy) financial

"Employee Stock Option (right to buy)"

Restricted Stock Units financial

"Each restricted stock unit represents a contingent right to receive one share"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Vesting Commencement Date financial

"September 21, 2026 (the "Vesting Commencement Date")"

The vesting commencement date is the starting point when an employee begins earning ownership rights to their promised benefits, such as stock options or retirement contributions. Think of it like the day a savings account is opened—only after this date do the benefits start to grow and become fully available over time. It matters to investors because it marks when the clock begins ticking toward full ownership, affecting the timing and value of these benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What is the vesting schedule for Robert Paul Myers’s MIRM awards?

One-quarter of the options vest one year after September 21, 2026, and the balance vests in 36 successive equal monthly installments measured from the first anniversary. One-third of the RSUs vest on each anniversary of September 21, 2026, with the full award vested on the third anniversary.

What does each MIRM restricted stock unit represent?

Each restricted stock unit represents a contingent right to receive one share of Mirum Pharmaceuticals, Inc. common stock.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Available on EDGAR 10/14/2026 - 04:07 PM EDT Accepted by SEC EDGAR 10/14/2026 - 04:06 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Myers Robert Paul

(Last)

(First)

(Middle)

C/O MIRUM PHARMACEUTICALS, INC.

989 E. HILLSDALE BLVD., SUITE 300

(Street)

FOSTER CITY

CALIFORNIA

94404

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Mirum Pharmaceuticals, Inc. [ MIRM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Medical Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
10/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Employee Stock Option (right to buy)	$86.01	10/09/2026		A		40,000		⁽¹⁾	10/08/2036	Common Stock	40,000	$0	40,000	D
Restricted Stock Units	⁽²⁾	10/09/2026		A		25,000		⁽³⁾	⁽³⁾	Common Stock	25,000	$0	25,000	D

Explanation of Responses:

1. 1/4th of the shares vest one year after September 21, 2026 (the "Vesting Commencement Date") and the balance of the shares vest in a series of 36 successive equal monthly installments measured from the first anniversary of the Vesting Commencement Date.

2. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

3. 1/3rd of the shares subject to the restricted stock units shall vest on each anniversary of September 21, 2026 (the "Vesting Commencement Date"), such that the entire award will be vested on the three-year anniversary of the Vesting Commencement Date.

	/s/ Judit Ryvkin, Attorney-in-Fact	10/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR